The global cell and gene therapy clinical trials market size accounted for USD 13.32 billion in 2024, grew to USD 15.33 billion in 2025 and is projected to surpass around USD 54.29 billion by 2034, representing a healthy CAGR of 15.09% between 2024 and 2034. The North America cell and gene therapy clinical trials market size is calculated at USD 6.53 billion in 2024 and is expected to grow at a fastest CAGR of 15.19% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Clinical Trials Market, by Phase, 2024-2034
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Cell and Gene Therapy Clinical Trials Market, by Indication, 2024-2034
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. CNS
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Musculoskeletal
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Dermatology
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Endocrine, Metabolic, Genetic
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Immunology & Inflammation
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Ophthalmology
9.1.9.1. Market Revenue and Forecast (2021-2034)
9.1.10. Hematology
9.1.10.1. Market Revenue and Forecast (2021-2034)
9.1.11. Gastroenterology
9.1.11.1. Market Revenue and Forecast (2021-2034)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Phase (2021-2034)
10.1.2. Market Revenue and Forecast, by Indication (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Phase (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Phase (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Phase (2021-2034)
10.2.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Phase (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Phase (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Phase (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Phase (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Phase (2021-2034)
10.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Phase (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Phase (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Phase (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Phase (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Phase (2021-2034)
10.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Phase (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Phase (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Phase (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Phase (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Indication (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Phase (2021-2034)
10.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Phase (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Phase (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1. IQVIA
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. ICON Plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Laboratory Corporation of America Holdings
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Charles River Laboratories International, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. PAREXEL International Corp.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Syneos Health
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medpace Holdings, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PPD Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novotech
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Veristat, LLC
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample